blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2236155

EP2236155 - Decreasing potential iatrogenic risks associated with influenza vaccines [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  05.08.2019
Database last updated on 03.04.2025
Most recent event   Tooltip09.08.2019Revocation of patentpublished on 11.09.2019  [2019/37]
Applicant(s)For all designated states
Novartis Vaccines and Diagnostics GmbH
Emil-von-Behring-Strasse 76
35041 Marburg / DE
[2010/40]
Inventor(s)01 / Gregersen, Jens Peter
Novartis Vaccines and Diagnostics GmbH
Emil-von-Behring Strasse 76
35041 Marburg / DE
 [2012/20]
Former [2010/40]01 / Gregersen, Jens Peter
Novartis Vaccines and Diagnostics GmbH Emil-von-Behring Strasse 76
35041 Marburg / DE
Representative(s)Marshall, Cameron John
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2012/20]Marshall, Cameron John
Carpmaels & Ransford One Southampton Row London
WC1B 5HA / GB
Former [2010/40]Marshall, Cameron John
Carpmaels & Ransford One Southampton Row London
WC1B 5HA / GB
Application number, filing date10075310.209.09.2005
[2010/40]
Priority number, dateEP2004025547109.09.2004         Original published format: EP 04255471
[2010/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2236155
Date:06.10.2010
Language:EN
[2010/40]
Type: B1 Patent specification 
No.:EP2236155
Date:16.05.2012
Language:EN
[2012/20]
Search report(s)(Supplementary) European search report - dispatched on:EP01.09.2010
ClassificationIPC:A61K39/145, C12Q1/70
[2010/40]
CPC:
A61K39/145 (EP,US); C12N7/00 (US); A61K39/12 (EP,US);
A61P31/12 (EP); A61P31/16 (EP); A61P37/04 (EP);
C12Q1/70 (US); C12Q1/701 (US); G01N33/56983 (US);
C12N2760/16034 (US); C12N2760/16051 (EP,US); C12N2760/16134 (EP,US);
C12N2760/16234 (EP,US); G01N2333/11 (US); Y02A50/30 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/40]
Extension statesAL04.11.2010
BA04.11.2010
HR04.11.2010
MK04.11.2010
YU04.11.2010
TitleGerman:Verminderung von potentiellen iatrogenen Risiken in Verbindung mit Influenza Impfstoffen[2010/42]
English:Decreasing potential iatrogenic risks associated with influenza vaccines[2010/40]
French:Réduction de risques iatrogènes potentiels associés aux vaccins contre la grippe[2010/42]
Former [2010/40]Verringerung potentieller iatrogener Risiken, die mit Influenza-Impfstoffen zusammenhängen
Former [2010/40]Diminution des risques iatrogéniques potentiels associés aux vaccins contre la grippe
Examination procedure06.10.2010Amendment by applicant (claims and/or description)
06.10.2010Examination requested  [2010/46]
03.01.2011Despatch of a communication from the examining division (Time limit: M04)
17.01.2011Reply to a communication from the examining division
28.03.2011Despatch of a communication from the examining division (Time limit: M04)
10.06.2011Reply to a communication from the examining division
11.01.2012Communication of intention to grant the patent
27.03.2012Fee for grant paid
27.03.2012Fee for publishing/printing paid
Parent application(s)   TooltipEP05795012.3  / EP1789084
Divisional application(s)EP12157945.2  / EP2471551
EP12193096.0  / EP2578229
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20050795012) is  15.05.2008
Opposition(s)Opponent(s)01  18.02.2013  25.02.2013  ADMISSIBLE
Janssen Vaccines & Prevention B.V.
Archimedesweg 4
2333 CN Leiden / NL
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB, et al, et al
Siebertstrasse 3
81675 München / DE
 [2016/39]
Former [2015/08]
Opponent(s)01  18.02.2013  25.02.2013  ADMISSIBLE
Crucell Holland B.V.
Archimedesweg 4
2333 CN Leiden / NL
Opponent's representative
Vossius & Partner, et al, et al
Siebertstrasse 3
81675 München / DE
Former [2013/13]
Opponent(s)01  18.02.2013   
Crucell Holland B.V.
Archimedesweg 4
2333 CN Leiden / NL
Opponent's representative
Wachenfeld, Joachim, et al, et al
Vossius & Partner Siebertstrasse 4
81675 München / DE
22.03.2013Invitation to proprietor to file observations on the notice of opposition
01.10.2013Reply of patent proprietor to notice(s) of opposition
04.03.2015Date of oral proceedings
23.04.2015Despatch of minutes of oral proceedings
08.05.2015Despatch of interlocutory decision in opposition
21.05.2019Legal effect of revocation of patent [2019/37]
17.07.2019Despatch of communication that the patent will be revoked
Appeal following opposition17.07.2015Appeal received No.  T1464/15
18.09.2015Statement of grounds filed
11.02.2016Invitation to file observations in an appeal (Time limit: M04) [2016/07]
20.06.2016Date of receipt of observations in an appeal [2016/25]
21.05.2019Result of appeal procedure: revocation of the patent
21.05.2019Date of oral proceedings
03.06.2019Minutes of the oral proceedings despatched
Fees paidRenewal fee
19.07.2010Renewal fee patent year 03
19.07.2010Renewal fee patent year 04
19.07.2010Renewal fee patent year 05
19.07.2010Renewal fee patent year 06
29.09.2011Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
BG08.08.2017
AT09.09.2017
CZ09.09.2017
GB09.09.2017
IE09.09.2017
IT09.09.2017
PL09.09.2017
TR09.09.2017
ES10.09.2017
BE30.09.2017
CH30.09.2017
DK30.09.2017
LI30.09.2017
NL01.10.2017
FR02.10.2017
DE04.04.2018
[2019/22]
Former [2019/16]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
BG08.08.2017
AT09.09.2017
CZ09.09.2017
GB09.09.2017
IE09.09.2017
IT09.09.2017
TR09.09.2017
ES10.09.2017
BE30.09.2017
CH30.09.2017
DK30.09.2017
LI30.09.2017
NL01.10.2017
FR02.10.2017
DE04.04.2018
Former [2019/13]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
BG08.08.2017
AT09.09.2017
CZ09.09.2017
GB09.09.2017
IE09.09.2017
IT09.09.2017
ES10.09.2017
BE30.09.2017
CH30.09.2017
DK30.09.2017
LI30.09.2017
NL01.10.2017
FR02.10.2017
DE04.04.2018
Former [2019/10]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
BG08.08.2017
AT09.09.2017
CZ09.09.2017
GB09.09.2017
IE09.09.2017
IT09.09.2017
BE30.09.2017
CH30.09.2017
DK30.09.2017
LI30.09.2017
NL01.10.2017
FR02.10.2017
DE04.04.2018
Former [2018/51]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
BG30.09.2015
AT09.09.2017
CZ09.09.2017
GB09.09.2017
IE09.09.2017
IT09.09.2017
BE30.09.2017
CH30.09.2017
DK30.09.2017
LI30.09.2017
NL01.10.2017
FR02.10.2017
DE04.04.2018
Former [2018/39]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
BG30.09.2015
AT09.09.2017
CZ09.09.2017
GB09.09.2017
IE09.09.2017
IT09.09.2017
BE30.09.2017
CH30.09.2017
LI30.09.2017
NL01.10.2017
FR02.10.2017
DE04.04.2018
Former [2018/37]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
BG30.09.2015
CZ09.09.2017
GB09.09.2017
IE09.09.2017
BE30.09.2017
CH30.09.2017
LI30.09.2017
NL01.10.2017
FR02.10.2017
DE04.04.2018
Former [2018/36]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
BG30.09.2015
CZ09.09.2017
GB09.09.2017
IE09.09.2017
BE30.09.2017
CH30.09.2017
LI30.09.2017
NL01.10.2017
DE04.04.2018
Former [2018/35]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
BG30.09.2015
CZ09.09.2017
GB09.09.2017
IE09.09.2017
CH30.09.2017
LI30.09.2017
NL01.10.2017
DE04.04.2018
Former [2018/34]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
BG30.09.2015
CZ09.09.2017
IE09.09.2017
CH30.09.2017
LI30.09.2017
NL01.10.2017
DE04.04.2018
Former [2018/21]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
BG30.09.2015
CZ09.09.2017
Former [2017/40]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
BG30.09.2015
Former [2016/36]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
SK09.09.2015
SI10.09.2015
Former [2015/39]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
HU10.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
Former [2015/37]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
GR03.04.2015
Former [2015/35]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
SE10.09.2014
EE30.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
Former [2015/26]CY09.09.2014
FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
SE10.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
Former [2015/24]FI09.09.2014
LT09.09.2014
LU09.09.2014
LV09.09.2014
RO09.09.2014
SE10.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
Former [2015/23]FI09.09.2014
LT09.09.2014
LU09.09.2014
RO09.09.2014
MC30.09.2014
PT09.03.2015
IS31.03.2015
Former [2015/22]LT09.09.2014
LU09.09.2014
RO09.09.2014
MC30.09.2014
PT09.03.2015
Former [2015/20]LT09.09.2014
MC30.09.2014
Documents cited:Search[A]EP1108787  (CRUCELL HOLLAND BV [NL]) [A] 1-14* example 9 *;
 [X]US6344354  (WEBSTER ROBERT G [US], et al) [X] 10-14 * column 7, lines 59-67; claim 1 *;
 [X]  - LEVANDOWSKI R A, "Regulatory perspective in the United States on cell cultures for production of inactivated influenza virus vaccines.", DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION. 1999, (1999), vol. 98, ISSN 0301-5149, pages 171 - 175 ; DIS, XP009060109 [X] 1-14 * page 173, paragraph L - page 174, paragraph 2; table 2 *
 [X]  - BRANDS R ET AL, "InfluvacTC: A safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine", DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION; INACTIVATED INFLUENZA VACCINES PREPARED IN CELL CULTURE S. KARGER AG, P.O. BOX, ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND; S. KARGER AG, NEW YORK, NEW YORK, USA SERIES : DEVELOPMENTS IN BIOLOGICAL S, & MEETING OF THE NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL; HERTS, ENGLAND, UK; SEPTEMBER 26-27, 1997, (1999), pages 93 - 100, XP009060107 [X] 1-14 * page 95, line 9 - page 96, line 10; table 1 *
by applicantUS5292506
 WO9419013
 WO9615231
 EP0721782
 WO9737000
 US5948410
 WO0122992
 US6372223
 WO02097072
 US6534065
 WO03076601
 WO2005042728
    - BRANDS ET AL., DEV BIOL STAND, (1999), vol. 98, pages 93 - 100
    - HALPERIN ET AL., VACCINE, (2002), vol. 20, pages 1240 - 7
    - TREE ET AL., VACCINE, (2001), vol. 19, pages 3444 - 50
    - KISTNER ET AL., VACCINE, (1998), vol. 16, pages 960 - 8
    - KISTNER ET AL., DEV BIOL STAND, (1999), vol. 98, pages 101 - 110
    - BRUHL ET AL., VACCINE, (2000), vol. 19, pages 1149 - 58
    - PAU ET AL., VACCINE, (2001), vol. 19, pages 2716 - 21
    - PUPPE ET AL., J CLIN VIROL, (2004), vol. 30, pages 165 - 74
    - LEARY ET AL., J CLIN MICROBIOL, (2002), vol. 40, pages 1368 - 75
    - MAERTZDORF ET AL., J CLIN MICROBIOL, (2004), vol. 42, pages 981 - 6
    - ERDMAN ET AL., J CLIN MICROBIOL, (2003), vol. 41, pages 4298 - 303
    - MOSQUERA MDEL ET AL., J CLIN MICROBIOL, (2002), vol. 40, pages 111 - 6
    - DEFFERNEZ ET AL., J CLIN MICROBIOL, (2004), vol. 42, pages 3212 - 3218
    - COIRAS ET AL., JMED VIROL, (2004), vol. 72, pages 484 - 95
    - REID ET AL., J VIROL METHODS, (2004), vol. 116, pages 169 - 76
    - POON ET AL., J CLIN VIROL, (2004), vol. 30, pages 214 - 7
    - CAMPSALL ET AL., J CLIN MICROBIOL, (2004), vol. 42, pages 1409 - 13
    - HUANG ET AL., VET MICROBIOL, (2004), vol. 101, pages 209 - 14
    - MAYALL ET AL., J CLIN PATHOL, (2003), vol. 56, pages 728 - 30
    - WHILEY ET AL., JMED VIROL, (2004), vol. 72, pages 467 - 72
    - HATTERMANN ET AL., XENOTRANSPLANTATION, (2004), vol. 11, pages 284 - 94
    - NOVOA ET AL., VET RES, (1995), vol. 26, pages 493 - 8
    - BLAKE ET AL., J CLIN MICROBIOL, (1995), vol. 33, pages 835 - 9
    - HUCKRIEDE ET AL., METHODS ENZYMOL, (2003), vol. 373, pages 74 - 91
    - GREENBAUM ET AL., VACCINE, (2004), vol. 22, pages 2566 - 77
    - ZURBRIGGEN ET AL., EXPERT REV VACCINES, (2003), vol. 2, pages 295 - 304
    - PIASCIK, JAM PHARM ASSOC (WASH DC), (2003), vol. 43, pages 728 - 30
    - MANN ET AL., VACCINE, (2004), vol. 22, pages 2425 - 9
    - HALPERIN ET AL., AM JPUBLIC HEALTH, (1979), vol. 69, pages 1247 - 50
    - HERBERT ET AL., J INFECT DIS, (1979), vol. 140, pages 234 - 8
    - CHEN ET AL., VACCINE, (2003), vol. 21, pages 2830 - 6
    - HEHME ET AL., VIRUS RES, (2004), vol. 103, pages 163 - 71
    - COOPER ET AL., VACCINE, (2004), vol. 22, pages 3136 - 43
    - FREY ET AL., VACCINE, (2003), vol. 21, pages 4234 - 7
    - BOZKIR; HAYTA, DRUG TARGET, (2004), vol. 12, pages 157 - 64
    - GUEBRE-XABIER ET AL., J VIROL, (2003), vol. 77, pages 5218 - 25
    - PEPPOLONI ET AL., EXPERT REV VACCINES, (2003), vol. 2, pages 285 - 93
    - PINE ET AL., J CONTROL RELEASE, (2002), vol. 85, pages 263 - 70
    - BALDRIDGE ET AL., VACCINE, (2000), vol. 18, pages 2416 - 25
    - BANZHOFF, IMMUNOLOGY LETTERS, (2000), vol. 71, pages 91 - 96
    - ADAMSON, DEV BIOL STAND, (1998), vol. 93, pages 89 - 96
    - GOOSSENS ET AL., ARTHRITIS RHEUM, (2001), vol. 44, pages 570 - 7
    - FALLAUX ET AL., HUM GENE THER, (1998), vol. 9, pages 1909 - 17
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.